

**BEST AVAILABLE COPY.**

**Exhibit B**

## Thrombosis

# Blockade of the Platelet P2Y<sub>12</sub> Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model

Kai Wang, Xiaorong Zhou, Zhongmin Zhou, Khaldoun Tarakji, Marcelo Carneiro, Marc S. Penn, Daniel Murray, Allan Klein, Robert G. Humphries, Jonathan Turner, James D. Thomas, Eric J. Topol, A. Michael Lincoff

**Objective**—Reperfusion therapy for myocardial infarction is limited by a significant reocclusion rate and less optimal myocardial tissue perfusion due to excessive platelet accumulation and recruitment at the sites of vascular injury. We assessed the influence of a selective P2Y<sub>12</sub>-receptor antagonist (AR-C69931MX), in conjunction with thrombolytic therapy, on the prevention of platelet aggregation and thrombus formation.

**Methods and Results**—A canine coronary electrolytic injury thrombosis model was used. Tissue-type plasminogen activator (t-PA; 1 mg/kg in phase I, 0.5 mg/kg in phase II in the AR-C69931MX group, and 1 mg/kg in the placebo group in phase I and II) was administered 30 minutes after thrombus formation; either saline or AR-C69931MX (4  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ ) was given to all animals intravenously 10 minutes before t-PA administration for a total of 2 hours. All animals received heparin (80 U/kg) as an intravenous bolus followed by a continuous infusion of 17 U  $\cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ . Myocardial tissue perfusion was evaluated by use of the colored microsphere technique and real-time myocardial contrast echocardiography. The incidences of reocclusion and cyclic flow variation were significantly decreased in the AR-C69931MX group ( $P < 0.05$ ). Myocardial tissue flow with AR-C69931MX treatment improved significantly at 20 and 120 minutes after reflow, whereas tissue flow with placebo remained at a level similar to that during occlusion ( $P < 0.05$ ).

**Conclusions**—The adjunctive administration of AR-C69931MX blocked ADP-mediated platelet aggregation and recruitment and prevented platelet-mediated thrombosis, resulting in prolongation of reperfusion time and a decrease in reocclusion and cyclic flow variations. Importantly, myocardial tissue perfusion was significantly improved in the P2Y<sub>12</sub> antagonist group. (*Arterioscler Thromb Vasc Biol.* 2003;23:357-362.)

**Key Words:** P2Y<sub>12</sub> receptor ■ thrombosis ■ myocardial tissue perfusion ■ myocardial contrast echocardiography

Although much progress has been made in the treatment of ischemic heart disease during the past decades, acute ischemic complications due to excessive platelet accumulation, platelet recruitment, and thrombus formation remain a challenging therapeutic issue. Traditionally, successful reperfusion after acute myocardial infarction has been considered to be restored patency of epicardial coronary arteries. Increasing evidence indicates, however, that an open epicardial coronary artery may not represent "optimal reperfusion" and that adequate myocardial tissue perfusion is at least as important as sustained epicardial coronary patency. Lack of myocardial perfusion at the tissue level, despite restoration of normal anterograde flow in the epicardial infarct-related artery, predicts poor recovery of left ventricular function in acute myocardial infarction.<sup>1</sup> ADP-induced platelet activation plays a pivotal role in thrombus formation and thus, inhibition

of this pathway holds promise as a means of significantly reducing clot formation and improving myocardial tissue reperfusion during acute ischemic states. There are 2 subtypes of ADP receptor on platelets: P2Y<sub>1</sub> and P2Y<sub>12</sub> receptor. P2Y<sub>1</sub> is found in other tissues, whereas the P2Y<sub>12</sub> receptor, previously referred to as P<sub>2T</sub>, is found only on platelets, megakaryocytes, and astroglial cells of the brain.<sup>2-6</sup>

### See page 158

The thienopyridines, including ticlopidine and clopidogrel, are platelet ADP receptor antagonists that act at the level of P2Y<sub>12</sub> receptor.<sup>7,8</sup> However, their effects on platelets are slow and irreversible,<sup>9</sup> and they show only moderate inhibition of ADP-induced platelet aggregation at the current therapeutic doses.<sup>10</sup> ATP is the natural antagonist of ADP-induced platelet aggregation through competitive binding of the plate-

Received October 16, 2002; revision accepted December 4, 2002.

From the Department of Cardiovascular Medicine (K.W., X.Z., Z.Z., K.T., M.C., M.S.P., D.M., A.K., J.D.T., E.J.T., A.M.L.), The Cleveland Clinic Foundation, Cleveland, Ohio, and Astra-Zeneca (R.G.H., J.T.), R & D, Charnwood, England.

Correspondence to Kai Wang, MD, PhD, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, F25, Cleveland, OH 44195. E-mail wangk@ccf.org

© 2003 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol.* is available at <http://www.atvbaha.org>

DOI: 10.1161/01.ATV.0000052669.50791.0B

let ADP P2Y<sub>12</sub> receptor.<sup>11,12</sup> The ATP analogue AR-C69931MX, a novel, selective, and specific P2Y<sub>12</sub> receptor antagonist, was recently synthesized.<sup>12</sup> Initial animal studies suggested that this analogue inhibited arterial thrombosis with less effect on bleeding time compared with platelet glycoprotein IIb/IIIa receptor antagonists.<sup>12</sup> Recently, AR-C69931MX has been shown to be effective in preventing the development of thrombosis in a canine model of electrolytic carotid arterial injury.<sup>13</sup> In this study, we evaluated the effect of AR-C69931MX, in conjunction with thrombolytic therapy, on reperfusion and the prevention of reocclusion in a canine coronary thrombosis model. Furthermore, the influence of AR-C69931MX on myocardial microvascular reperfusion and tissue perfusion was studied by myocardial contrast echocardiography (MCE).

## Methods


### Surgical Preparation

A canine coronary electrolytic injury thrombosis model was used as described previously<sup>14</sup> with hound dogs (20 to 22 kg) of either sex. In brief, after induction of anesthesia with intravenous sodium pentobarbital (25 mg/kg) and intubation, a left thoracotomy was performed through the fifth intercostal space. A 2-cm segment of left circumflex coronary artery (LCX) was isolated, and a Doppler ultrasonic flow probe (Crystal Biotech) was placed around the vessel for the measurement of coronary blood flow (CBF). CBF was monitored and recorded on a digital data-acquisition system (Gould Instrument System, Inc). Thrombosis was induced with the electrolytic injury technique.<sup>14</sup> The endothelium of the LCX was manually injured by gently rubbing the artery distal to the flow probe. A coronary electrode, consisting of silver-coated copper wire with a 26-gauge needle tip, was then inserted into the isolated and injured segment of the LCX, ensuring its contact with the intraluminal surface of the vessel. Visual inspection for proper position of the electrode in the artery during the experiment was performed, and visual evidence of vessel wall injury surrounding the electrode was assessed at the end of experiment. Distal to the flow probe and the electrode, a vascular occluder was placed around the vessel and then adjusted to induce 80% stenosis. Thrombosis was initiated by delivery of a 100- $\mu$ A continuous anodal current to the tip of the coronary electrode, and formation of a fully occlusive coronary thrombus was determined by zero CBF. The occluder was gradually removed, and electrical stimulation was then suspended. Throughout the procedure, the electrocardiogram was continuously monitored to determine heart rate and S-T segment elevation. Blood gas analysis was performed to maintain the pH and arterial blood gases within physiological range. All experiments conformed to the position of the American Heart Association on research animal use and care and were conducted with the approval of the Animal Research Committee of the Cleveland Clinic Foundation.

### Experimental Protocol and Drug Administration

All animals received aspirin (325 mg) orally on the day of the procedure. After the occluder was removed and electrical stimulation was turned off, 30 minutes were allowed to elapse to confirm the stability of thrombosis before administration of tissue-type plasminogen activator (t-PA; Figure 1). Twenty minutes after thrombus formation (10 minutes before t-PA was given), the dogs were randomized to receive either saline or AR-C69931MX (4  $\mu$ g  $\cdot$  kg<sup>-1</sup>  $\cdot$  min<sup>-1</sup>) intravenously for a total of 2 hours. Simultaneously with administration of t-PA, heparin was given as an 80 U/kg IV bolus followed by a continuous infusion of 17 U  $\cdot$  kg<sup>-1</sup>  $\cdot$  h<sup>-1</sup> for the subsequent duration of the experiment.

Two phases were included in this study. In phase I, t-PA (1 mg/kg) was administered IV to all animals (placebo group=10, AR-C69931MX group=10) for 20 minutes. In phase II, the dogs from the placebo group (n=10) were given 1 mg/kg t-PA, whereas only



**Figure 1.** Schematic diagram of experimental protocol. Thrombus formation is induced by passage of 100- $\mu$ A continuous anodal current through the coronary electrode. Twenty minutes after thrombus formation, dogs received either AR-C69931MX (4  $\mu$ g  $\cdot$  kg<sup>-1</sup>  $\cdot$  min<sup>-1</sup>) or saline. Ten minutes afterward, t-PA was given to all animals for a 20-minute period (phase I, 1 mg/kg; phase II, 0.5 mg/kg). Colored microspheres were injected directly into the left atrium before thrombus formation, as control, during the occlusion, and at the end of adjunctive treatment administration. MCE was performed before thrombus formation, during occlusion, 20 minutes after t-PA infusion, and at the end of adjunctive treatment administration. All animals from both phases received heparin (80 U/kg as a bolus, 17 U  $\cdot$  kg<sup>-1</sup>  $\cdot$  min<sup>-1</sup> IV).

0.5 mg/kg t-PA was administered to the animals in the AR-C69931MX group (n=10). The purpose of this second phase was to investigate whether prevention of reocclusion and cyclic flow variation (CFV) could still be achieved by a lower dose of t-PA combined with AR-C69931MX adjunctive therapy. In phase II, myocardial tissue blood flow (TBF) was evaluated with a standard fluorescent color microsphere technique and MCE at baseline, during occlusion, and at the end of the experiments.

Thrombolysis was defined as restoration of CBF to at least 30% of the baseline value, occurring at any time after the onset of drug infusion.<sup>15</sup> Reocclusion was defined as occurrence of zero CBF after successful thrombolysis.<sup>15</sup> The animals were observed for a 2-hour period after the occurrence of thrombolysis for evidence of reocclusion. If reocclusion did not occur, the maximal duration of reperfusion was considered to be 120 minutes. In those animals with intermittent CBF restoration due to CFVs, the total duration of reperfusion was calculated as the length of time during which blood flow was greater than zero during the 2-hour period after onset of reperfusion. Two hours after the onset of thrombolysis, animals with persistent zero blood flow as well as those with CFVs were considered to have reocclusion of the coronary artery. Xylocaine was administered to control ventricular arrhythmias when it was necessary.

### Measurement of Myocardial TBF

In phase II, myocardial TBF was measured with a standard fluorescent color microsphere technique on a blinded basis.<sup>16</sup> Three different fluorescent color microspheres (Triton Technology Inc) were injected directly into the left atrium at baseline, during occlusion, and at the end of the experiment. Reference blood samples were simultaneously withdrawn from the carotid artery at a predetermined rate of 5.8 mL/min by a calibrated withdrawal pump (Harvard Apparatus). Tissue samples from the epicardial and endocardial regions of the area at risk and nonischemic area were taken. After tissue digestion, the microsphere content was spectrophotometrically measured (spectrofluorometer FP-777). The value of TBF in the area at risk and nonischemic area was calculated as the average of corresponding epicardial and endocardial flows.

### Myocardial Contrast Echocardiography

In phase II, real-time harmonic MCE was performed at baseline, during occlusion, 20 minutes after t-PA infusion, and at the end of

TABLE 1. Thrombolytic Effects of IPA with Heparin, AR-C69931MX

	Phase I		Phase II	
	Placebo (n=10)	AR-C69931MX (n=10)	Placebo (n=10)	AR-C69931MX (n=10)
Reperfusion rate, %	100	100	100	100
Time to reflow, min	24.7±7.9	20.9±9.1	21.8±6.4	21.8±5.8
Reflow duration time, min	75.0±39.9	120±0*	86.1±45.2	120±0*
Cyclic flow variation rate, %	50	0*	20	0*
Reocclusion rate, %	60	0*	40	0*

\*P&lt;0.05 compared with placebo group.

the experiments. Previous experimental and clinical studies had shown that MCE is a reliable, noninvasive method to quantify myocardial tissue perfusion.<sup>17,18</sup> The heart was imaged in the short-axis view with a GE Vingmed/VividFiVe. The echocardiographic contrast agent used in this study was Definity (Dupont). One vial was diluted in 50 mL of normal saline solution, and the contrast agent was infused with a syringe pump at a rate of 4 mL/h. The area at risk was defined as delayed replenishment (1 to 2 seconds after burst) in the LCX territory. After full replenishment, the patchy area or the area without contrast was considered to be the infarct area. To determine myocardial perfusion at the tissue level, video intensity (in decibels) was measured at different time points and fitted into the exponential model  $y = A \times [1 - e^{-(t-\tau)/\tau}]$ . The reperfusion rate ( $A/\tau$ ) was calculated at each time point. All data analysis was performed with EchoPAC software (version 6.3.1) on a blinded basis.

#### Platelet Aggregation

Peripheral venous blood samples were collected in 3.8% sodium citrate (9:1, vol/vol) before treatment at baseline, at the end of t-PA infusion, and at the end of adjunctive treatment. Platelet-rich plasma was obtained by centrifuging the blood at 150g for 15 minutes at 24°C. Platelet-poor plasma was obtained by further centrifugation at 1500g for 15 minutes. Platelet counts in platelet-rich plasma were adjusted to  $2.5 \times 10^5$  cells/mL. Aggregation was determined in a light-transmission aggregometer (Chronolog Corp) in response to ADP (20  $\mu$ mol/L) and ADP (20  $\mu$ mol/L) plus epinephrine (5  $\mu$ mol/L).

#### Coagulation Study and Bleeding Time

Blood samples were taken at the same time points as those for platelet aggregation study for measurement of prothrombin time and activated partial thromboplastin time by standard techniques with the ST4 coagulation timer (Diagnostica Stago).<sup>15</sup> Gum bleeding time was performed to determine the effect of AR-C69931MX on bleeding time. Incision of the inner lip was carried out with a fully automated incision instrument (Surgicutt, International Technidyne Co). Every 30 seconds after the incision was made, the flow of blood was wicked with blotting paper until it stopped.

#### Determination of Infarct Size

At the end of the experiment, the animals were euthanatized with an IV overdose of pentobarbital (77 mg/kg) and potassium chloride (120 mg/kg), the heart was excised, and infarct size and the area at risk were determined with the ex vivo dual-perfusion histochemical method. The LCX and left anterior descending coronary artery (LAD) were cannulated and perfused with 1.5% triphenyltetrazolium chloride in the LCX and with Evans blue in the LAD simultaneously at a pressure of 100 mm Hg for 10 minutes at 37°C. After fixation with 10% formalin for 2 hours, the heart was sectioned into 5 transverse slices, and the infarct area and the area at risk were quantified by using a computerized image analyzer system (Image-Pro Plus, version 4.0 for Windows, Media Cybernetics) on a blinded basis.

#### Statistical Analysis

Statistical analysis was performed with use of SPSS software (version 7.0 for Windows, SPSS Inc). Data are presented as mean  $\pm$  SD. Continuous variables were compared by unpaired *t* tests. Perfusion data were analyzed with a repeated-measures ANOVA with a post hoc Tukey's honestly significant difference test. A value of  $P \leq 0.05$  was considered to be statistically significant.

#### Results

##### Effects of Adjunctive AR-C69931MX on Thrombolysis and Acute Reocclusion


The comparative thrombolytic effects in the 2 groups are shown in Table 1. Baseline CBF was similar in the 2 groups in both phases. The mean time required for occlusive thrombus formation was also similar in the 2 groups (37.6 $\pm$ 14.3 minutes in the AR-C69931MX groups vs 41.7 $\pm$ 9.8 minutes in the placebo groups,  $P$ =NS). No acceleration in thrombolysis or increased reperfusion rate was observed in AR-C69931MX groups compared with placebo groups. However, there were significant differences in the incidence of reocclusion and CFV between the 2 groups. In AR-C69931MX groups, there was no reocclusion or CFV, but reocclusion occurred in 6 of 10 animals (phase I) and in 4 of 10 animals (phase II), and CFV occurred in 5 of 10 animals (phase I) and in 2 of 10 animals (phase II) in the placebo groups.

##### Myocardial TBF

Myocardial TBF in the risk area as measured by colored microspheres was similar at baseline in the 2 groups (0.93 $\pm$ 0.65 mL  $\cdot$  min<sup>-1</sup>  $\cdot$  g<sup>-1</sup> with placebo and 0.90 $\pm$ 0.44 mL  $\cdot$  min<sup>-1</sup>  $\cdot$  g<sup>-1</sup> with AR-C69931MX group,  $P$ =NS). During coronary occlusion, TBF within the risk area was reduced to 0.30 $\pm$ 0.19 mL  $\cdot$  min<sup>-1</sup>  $\cdot$  g<sup>-1</sup> in the placebo group and to 0.32 $\pm$ 0.36 mL  $\cdot$  min<sup>-1</sup>  $\cdot$  g<sup>-1</sup> in the AR-C69931MX group ( $P$ =NS). By 120 minutes after initiation of the study drug, TBF with AR-C69931MX improved to 0.69 $\pm$ 0.41 mL  $\cdot$  min<sup>-1</sup>  $\cdot$  g<sup>-1</sup>, whereas TBF with placebo remained at 0.35 $\pm$ 0.20 mL  $\cdot$  min<sup>-1</sup>  $\cdot$  g<sup>-1</sup> ( $P$ <0.05) (Figure 2).

##### Myocardial Contrast Echocardiography

There was no difference in myocardial TBF at baseline and during occlusion between the 2 groups. However, the AR-C69931 MX group showed better microvascular perfusion than the placebo group (Figures 3 and 4) at 20 minutes (20.31 $\pm$ 13.71 dB/s vs 5.42 $\pm$ 4.43 dB/s;  $P$ <0.01) and 120 minutes (29.95 $\pm$ 17.89 dB/s vs 8.56 $\pm$ 6.16 dB/s;  $P$ <0.001) after thrombolysis. Moreover, the correlation between MCE



**Figure 2.** Myocardial TBF as assessed by colored microspheres at baseline, during occlusion, and at the end of adjunctive treatment administration. At baseline, myocardial TBF in the risk area was similar in both groups ( $P=NS$ ). During occlusion, a significant reduction in myocardial TBF within the risk area was observed, and there was no difference between the 2 groups. However, by 120 minutes after initiation of the study drug, myocardial TBF with AR-C69931MX improved greatly, whereas myocardial TBF with placebo remained at a level similar to that during occlusion ( $P<0.05$ ).


findings and triphenyltetrazolium chloride staining for assessment of the area at risk and infarct size was excellent ( $r=0.87$ ,  $P<0.0001$ ).

### Platelet Aggregation

The results of platelet-rich plasma platelet aggregation in response to ADP alone and ADP plus epinephrine are summarized in Table 2. There was no influence of t-PA alone on platelet aggregation. However, adjunctive administration of AR-C69931MX significantly decreased platelet aggregation by  $>98\%$  (ADP alone) and  $79\%$  (ADP plus epinephrine).

### Coagulation Study and Bleeding Time

After administration of t-PA, prothrombin time and activated partial thromboplastin time values were increased in all animals as expected, without any difference between the 2 groups. By the end of adjunctive therapy, there was no significant difference in prothrombin time and activated partial thromboplastin time between the 2 groups. Bleeding time was significantly prolonged (1.8- to 2.8-fold) owing to AR-C69931MX administration compared with the placebo



**Figure 3.** Myocardial microvascular flow as assessed by MCE at baseline, during occlusion, 20 minutes after t-PA infusion, and at the end of adjunctive treatment administration. There was no difference in myocardial TBF at baseline and during occlusion between the 2 groups. However, the AR-C69931MX group showed better microvascular perfusion than the placebo group at 20 minutes ( $20.31 \pm 13.71$  dB/s vs  $5.42 \pm 4.43$  dB/s;  $P<0.01$ ) and 120 minutes ( $29.95 \pm 17.89$  dB/s vs  $8.56 \pm 6.16$  dB/s;  $P<0.001$ ) after thrombolysis.

**TABLE 2.** Effects of AR-C69931 on PRP Platelet Aggregation

	Control, %	AR-C69931MX, %
<b>ADP</b>		
Baseline	54.9 $\pm$ 28.3	61.5 $\pm$ 26.0
End of tPA	50.5 $\pm$ 29.3	0.9 $\pm$ 1.9*
End of adjunctive	54.6 $\pm$ 19.9	1.6 $\pm$ 2.8*
<b>ADP + Epinephrine</b>		
Baseline	76.5 $\pm$ 15.2	68.0 $\pm$ 18.0
End of tPA	74.3 $\pm$ 19.6	7.6 $\pm$ 20.6*
End of adjunctive	69.8 $\pm$ 17.3	14.4 $\pm$ 23.6*

\* $P<0.001$  compared with placebo group.

group (end of t-PA,  $3.68 \pm 1.64$  minutes in the placebo group vs  $9.85 \pm 0.049$  minutes in the AR-C69931MX group,  $P<0.001$ ; end of adjunctive therapy,  $2.48 \pm 0.61$  minutes in the placebo group vs  $4.36 \pm 1.14$  minutes in the AR-C69931MX group,  $P<0.001$ ).

### Infarct Size

In both phases, infarct size was significantly reduced by  $\approx 50\%$  in the AR-C69931MX group when expressed either as percentage of the area at risk or as absolute infarct size (Table 3).

### Discussion

ADP is a key mediator of platelet aggregation and thrombosis, particularly under high-shear flow conditions characteristic of stenosed atherosclerotic arteries. In this study, we demonstrated that inhibition of ADP-mediated platelet aggregation and recruitment by the platelet ADP receptor-P2Y<sub>12</sub> receptor antagonist AR-C69931MX significantly prolonged reperfusion time and abolished reocclusion and CFVs, even with half of the dosage of t-PA in the same canine thrombosis/fibrinolysis model. These beneficial effects were achieved with only a modest increase in bleeding time in comparison with placebo. Most importantly, this study shows that combination therapy with a thrombolytic agent and antagonism of platelet aggregation not only maintains patency of epicardial coronary arteries but also improves myocardial microvascular perfusion and myocardial salvage.

Adenine nucleotides affect a number of cellular events. Activation of platelets by ADP is a receptor-mediated process involving 2 subtypes of the P2 receptor family: P2Y<sub>1</sub> and P2Y<sub>12</sub>.<sup>19</sup> The latter subtype (also historically referred to as P2<sub>7</sub>, P2Y<sub>AC</sub>, P2<sub>UT</sub>, or P2Y<sub>ADP</sub>) is found on platelets, megakaryocytes, and astroglial cells of the brain. It has been demonstrated that P2Y<sub>12</sub> receptor activation is important for the sustained platelet-aggregation response to ADP and for a significant component of the platelet response to other agonists.<sup>20,21</sup> The importance of this receptor pathway in arterial thrombosis is also suggested by the positive clinical findings with the thienopyridines, ticlopidine and clopidogrel,<sup>22,23</sup> which produce partial inhibition of P2Y<sub>12</sub>-mediated platelet activation after hepatic generation of an active metabolite.<sup>24</sup> Humbert and colleagues<sup>25</sup> further studied ADP-dependent platelet aggregation by using platelets from a patient lacking




Figure 4. Examples of MCE performed in an AR-C69931MX-treated dog (top) and in a control dog (bottom) at baseline, during occlusion, 20 minutes after t-PA infusion, and at the end of adjunctive treatment administration. In both groups, myocardial opacification was uniform at baseline. During occlusion, risk area was clearly delineated as an area of absent contrast opacification. However, at 20 minutes after t-PA infusion and at the end of adjunctive treatment administration, risk area from controls was still incompletely refilled by contrast, whereas it was uniformly opacified in AR-C69931MX-treated animals, indicating preserved myocardial microvascular flow.

the P2Y<sub>12</sub> receptor and normal platelets in the presence of clopidogrel. They found that ADP-induced aggregates of the patient's platelets and clopidogrel-treated normal platelets are composed of a small number of "loosely packed" platelets with fewer than normal contact points. Recently, Nurden et al<sup>26</sup> and Remijn et al<sup>27</sup> confirmed these findings and demonstrated that the platelets in a patient lacking the P2Y<sub>12</sub> receptor showed impaired ADP-dependent platelet aggregation, had much reduced ADP-binding capacity, and lacked the ability to inhibit cGMP levels in response to ADP. Platelet aggregation under physiological flow conditions in control blood incubated with AR-C69931MX was similarly impaired. The thrombi were smaller and morphologically abnormal in blood from the patient and control blood in the presence of AR-C69931MX. Thus, it is unclear whether the antithrombotic effect of AR-C69931MX is due to inhibition of platelet aggregation or to the formation of abnormal, fragile platelet aggregates.

AR-C69931MX is a novel, highly potent, and selective P2Y<sub>12</sub> receptor antagonist. In contrast to clopidogrel, its antiplatelet activity is not dependent on metabolic conversion, and in both healthy volunteers and patients, potent and complete inhibition of ADP-induced platelet aggregation has been observed ex vivo during intravenous infusion.<sup>28</sup> The pharmacokinetic profile of AR-C69931MX is characterized by rapid attainment of a steady-state plasma concentration and a rapid offset of effect on cessation of infusion. Huang and colleagues<sup>13</sup> have shown that AR-C69931MX displayed a rapid onset and offset of action with the ability to prevent occlusive arterial thrombus formation. This rapidly reversible characteristic may make this agent well suited for inhibiting platelet function under appropriate clinical conditions while reducing the risk of bleeding complications.

An important finding of this study is that restoration and maintenance of myocardial microvascular flow and tissue

perfusion were achieved with combination therapy of a thrombolytic agent and AR-C69931MX, as evidenced by MCE and myocardial TBF measurement. In the placebo group, the compromised myocardial tissue perfusion was not limited to the animals with CFV or reocclusion; a similar finding was observed in the animals without CFV or reocclusion, indicating that the difference in myocardial tissue perfusion was due to improvement of myocardium perfusion rather than a higher patency rate in the AR-C69931MX group. Increasing evidence suggests that although the patency of the infarct-related artery may have been reestablished, disordered microvascular function and inadequate myocardial tissue perfusion are often present after reperfusion therapy for acute myocardial infarction. Thus, optimal reperfusion should not only sustain epicardial patency but also restore microvascular flow and myocardial tissue perfusion. The potential explanation for this finding is that potent antiplatelet therapy may relieve microvascular obstructions caused by platelet-thrombin microemboli.

In summary, AR-C69931MX is a potent and selective inhibitor of ADP-induced platelet aggregation through its P2Y<sub>12</sub> receptor antagonistic property. The administration of AR-C69931MX in the canine coronary thrombosis model blocked ADP-induced platelet aggregation and recruitment and prevented platelet-mediated thrombosis. It prolongs reperfusion time, abolishes reocclusion and CFVs, and restores myocardial tissue perfusion with only a modest increase in bleeding time. This agent may be a useful adjunct during reperfusion therapy for acute myocardial infarction in humans.

### Acknowledgment

This study was support by a grant from Astra-Zeneca, R&D, Charnwood, England.

TABLE 3. Myocardial Area at Risk and Effect of AR-C69931MX on Infarct Size

	Phase I		Phase II	
	Placebo (n=10)	AR-C69931MX (n=10)	Placebo (n=10)	AR-C69931MX (n=10)
Area at risk, cm <sup>2</sup>	42.37±3.89	43.26±2.64	55.08±4.17	54.09±3.85
Infarct size, cm <sup>2</sup>	9.34±4.37	4.70±4.66*	17.79±7.50	9.87±5.89*
Percentage of infarct size at risk area, %	19.37±9.3	9.19±9.0*	32.47±13.93	18.33±11.52*

\*P<0.05 compared with placebo group.

## References

- Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T, Kitabatake A, Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. *Circulation*. 1992;85:1699-1705.
- Macfarlane DE, Mills DCB. The effect of ATP on platelets: evidence against the central role of released ADP in primary aggregation. *Blood*. 1975;46:309-320.
- Humphries RG, Tomlinson W, Clegg JA, Ingall AH, Kindon ND, Leff P. Pharmacological profile of the novel  $P_{2T}$  purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. *Br J Pharmacol*. 1995;115:1110-1116.
- Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet  $P_{2T}$  purinoceptors. *Br J Pharmacol*. 1994;113:1057-1063.
- Gordon JL. Extracellular ATP: effects, sources and fate. *Biochem J*. 1986;233:309-319.
- Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, Yang R-B, Nurdén P, Nurdén A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature*. 2001;409:202-207.
- Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Manucci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. *Thromb Haemost*. 1991;66:694-699.
- Savi P, Nurdén P, Nurdén A, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. *Platelets*. 1998;9:251-255.
- Schrör K. The basic pharmacology of ticlopidine and clopidogrel. *Platelets*. 1993;4:252-261.
- Boneu B, Destelle G, on behalf of the CAPRI Study Group. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. *Thromb Haemost*. 1996;76:939-943.
- Humphries RG, Robertson MJ, Leff P. A novel series of  $P_{2T}$  purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. *Trends Pharmacol Sci*. 1995;16:179-181.
- Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McNally JJ, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W. Antagonists of the platelet  $P_{2T}$ -receptor: a novel approach to antithrombotic therapy. *J Med Chem*. 1999;42:213-220.
- Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet  $P_{2T}$  receptor antagonist AR-C69931MX in a canine model. *JPET*. 2000;295:492-499.
- Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of antithrombotic agents. *Thromb Res*. 1980;17:841-853.
- Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. *Circulation*. 1994;89:1802-1809.
- Austin GE, Tuvlin MB, Martino-Salzman D, Hunter RL, Justicz AG, Thompson NK, Brooks AC. Determination of regional myocardial blood flow using fluorescent microspheres. *Am J Cardiovasc Pathol*. 1993;4:352-357.
- Tiemann K, Lohmeier S, Kuntz S, Koster J, Pohl C, Burns P, Nanda NC, Luderitz B, Becher H. Real-time contrast echo assessment of myocardial perfusion at low emission power: first experimental and clinical results using power pulse inversion imaging. *Echocardiography*. 1999;16:799-809.
- Masugata H, Peters B, Lafitte S, Strachan GM, Ohmori K, Demaria AN. Quantitative assessment of myocardial perfusion during graded coronary stenosis by real-time myocardial contrast echo refilling curves. *J Am Coll Cardiol*. 2001;37:262-269.
- Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation, I: evidence for three distinct ADP receptors on human platelets. *J Biol Chem*. 1998;273:2024-2029.
- Jarvis GE, Humphries RG, Robertson MJ, Leff P. ADP can induce aggregation of human platelets via both  $P_{2Y}$  and  $P_{2T}$ -receptors. *Br J Pharmacol*. 2000;129:275-282.
- Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the  $P_{2T}$ -receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. *Br J Haematol*. 2000;110:925-934.
- CAPRI Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRI). *Lancet*. 1996;348:1329-1339.
- The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 2001;345:494-502.
- Savi P, Combalbert J, Gaich C, Rouchon M-C, Maffrand J-P, Berger Y, Herbert J-M. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. *Thromb Haemost*. 1994;72:313-317.
- Humbert M, Nurdén P, Bihour C, Pasquet JM, Winckler J, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurdén AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. *Arterioscler Thromb Vasc Biol*. 1996;16:1532-1543.
- Nurdén P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurdén AT. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. *J Clin Invest*. 1995;95:1612-1622.
- Remijn JA, Wu YP, Jenning EH, Usseldijk MJW, van Willigen G, de Groot PG, Sixma JJ, Nurdén AT, Nurdén P. Role of ADP receptor  $P_{2Y_{12}}$  in platelet adhesion and thrombus formation in flowing blood. *Arterioscler Thromb Vasc Biol*. 2002;22:686-691.
- Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the  $P_{2T}$ -receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. *Thromb Haemost*. 2001;85:401-407.

Volume 23, Number 2, February 2003

ISSN 1079-5642

http://atvb.ahajournals.org

American Heart  
Association®



Fighting Heart Disease and Stroke


# Arteriosclerosis, Thrombosis, and Vascular Biology

HEALTH SCIENCES LIBRARY  
UNIVERSITY OF WISCONSIN

FEB 28 2003

1305 Linden Drive  
Madison, WI 53706

JOURNAL OF THE AMERICAN HEART ASSOCIATION



Atherosclerosis and Expression of MCP-1 Protein Are  
Greater in Aorta (Figure) Than Carotid Artery of WHHL.  
*Arterioscler Thromb Vasc Biol.* 2002;22:244-250.

## ■ Editorials

Omega-3 Fatty Acids and Cardiovascular Disease  
Triglyceride-Rich Lipoproteins and Vascular Function  
Statins and Stroke Protection  
Fast-Acting ADP Receptor Blockade in Thrombosis

## ■ Brief Review

CETP as a Target for Inhibiting Atherosclerosis

## ■ ATVB In Focus

Endothelial Dysfunction and Atherosclerotic Risk

## ■ Vascular Biology


Statin Increases Tetrahydrobiopterin  
Vascular and Renal Effects of Statins in ApoE<sup>-/-</sup> Mice  
Ephrin-B2 Forward and EphB4 Reverse Signaling  
PI3K Interacts With Cell Membrane ER  
Aging and Vascular p44/p42 MAP Kinase Activation  
Rho Kinase in VEGF-Induced Angiogenesis  
Increased [Ca<sup>2+</sup>]<sub>i</sub> Inhibits EC Migration  
Tissue Factor Expression Is Induced by LPA  
HEX as a Negative Regulator of Angiogenesis  
Chymase, FN Degradation, and SMC Apoptosis

## ■ Atherosclerosis and Lipoproteins

Regional Differences in Atherosclerosis in WHHL  
Ang II Generation in Human Arteries  
Expansive Remodeling in Atherosclerosis  
sPLA<sub>2</sub> and Atherosclerosis  
ApoE Polymorphisms and Cholesterol Efflux  
Phospholipid Hydroxyalkenals  
Rosiglitazone and MMP Levels in Diabetic Patients  
PPAR $\gamma$ 3 Gene Promoter Polymorphism  
Insulin Resistance and Atherosclerosis  
Family History and Early Carotid Atherosclerosis  
Vascular Dysfunction and Hypertriglyceridemia  
Small LDL Particles and CAD  
MRI Evaluation of Simvastatin Protection in Stroke  
PON Gene Cluster and CHD in Chinese Han Population  
Systematic Family Screening for FH in Iceland  
Plasma HDL-C QTL on Chromosome 16q  
IV MRI Coil and Atherosclerosis  
Bicuspid Aortic Valve

## ■ Thrombosis

P2Y<sub>12</sub> Receptor Blockade in a Canine Model

■ American Heart Association Scientific Statement 



# Arteriosclerosis, Thrombosis, and Vascular Biology

## Editorial Correspondence (Additional information available on the Internet at <http://www.atvbaha.org/misc/about.shtml>)

**EDITORIAL CORRESPONDENCE** should be sent to Donald Heistad, MD, *Editor-in-Chief*, Arteriosclerosis, Thrombosis, and Vascular Biology, Cardiovascular Center, 609 MRC, University of Iowa, Iowa City, Iowa 52242-1182. Telephone 319-353-5764. Fax 914-614-2121. E-mail [ATVB@uiowa.edu](mailto:ATVB@uiowa.edu). OR Professor James Scott, Arteriosclerosis, Thrombosis, and Vascular Biology, Department of Medicine, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom. Telephone 44-20-8383-8820. Fax 44-20-8383-2028. E-mail [arvb@ic.ac.uk](mailto:arvb@ic.ac.uk) OR Göran K. Hansson, MD, PhD, Arteriosclerosis, Thrombosis, and Vascular Biology, Center for Molecular Medicine, Karolinska Institute, Karolinska Hospital, S-17176 Stockholm, Sweden. Telephone (46) 8-51776693. Fax (46) 8-307966. E-mail: [Arvb@mm.ki.se](mailto:Arvb@mm.ki.se) OR Professor Akira Takeshita, MD, Arteriosclerosis, Thrombosis, and Vascular Biology, Research Institute of Angiocardiography and Cardiovascular Clinic, Kyushu University Faculty of Medicine, 3-1-1-Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Telephone 81-92-642-5355. Fax 81-92-642-5374. E-mail [atake@cardiol.med.kyushu-u.ac.jp](mailto:atake@cardiol.med.kyushu-u.ac.jp)

**INSTRUCTIONS TO AUTHORS** appear twice a year, in the January and July issues. Authors should consult these instructions before submitting manuscripts to Arteriosclerosis, Thrombosis, and Vascular Biology.

**AUTHOR COSTS** include page charges, cost of color figures, and cost of reprints, if ordered.

Statements, opinions, and results of studies published in Arteriosclerosis, Thrombosis, and Vascular Biology are those of the authors and do not reflect the policy or position of the American Heart Association, and the American Heart Association provides no warranty as to their accuracy or reliability.

## Business Correspondence (Additional information available on the Internet at <http://www.atvbaha.org/misc/about.shtml>)

**BUSINESS CORRESPONDENCE** should be sent to American Heart Association, Lippincott Williams & Wilkins, Subscription Fulfillment Dept., 351 West Camden Street, Baltimore, MD 21201-2436. Telephone 1-800-787-8984. Fax 1-800-787-8985. E-mail [custserv@lww.com](mailto:custserv@lww.com). Outside the U.S.: Telephone 410-361-8080. Fax 410-361-8048.

**CHANGE OF ADDRESS:** Please supply old and new addresses. Allow 4 weeks for changes.

**ANNUAL SUBSCRIPTION RATES:** U.S.: Personal \$290.00; Institutional \$499.00; Single copy \$48.00. Outside the U.S.: Personal \$354.00; Institutional \$554.00; Single copy \$48.00.

Medical professionals and scientists in training may subscribe for \$153 in the United States and \$186 outside the United States if payment is accompanied by a letter from the department chair verifying post held and completion date.

Prepayment is required. Make check, draft, or money order payable to the American Heart Association in US dollars drawn on a US bank, with Arteriosclerosis, Thrombosis, and Vascular Biology on the face of the check. To charge with a credit card, include account number, expiration date, and name as it appears on card.

For institutional rates in Japan, contact Nankodo Co, Ltd, 42-6 Hongo 3-chome, Bunkyo-ku, Tokyo 113, Japan. Telephone 03-3811-9950. Fax 03-3811-5031.

**REPRINTS:** For orders of fewer than 100, reprints are available from corresponding authors. Reprints in large quantities, for commercial or academic use, may be purchased from the publisher. For information and prices: telephone 410-528-4426. E-mail: [kibradle@lww.com](mailto:kibradle@lww.com)

## Advertising Correspondence (Additional information available on the Internet at <http://www.atvbaha.org/misc/about.shtml>)

**US ADVERTISING SALES:** The Jackson-Gaeta Group, Inc, 33 Small Avenue, Caldwell, NJ 07006. Telephone 973-403-7677. Fax 973-403-7795. Contact Joe Jackson, Craig Hawkins, Charles Novak. Media kits: Gail Sherba.

**JAPAN ADVERTISING SALES:** Biomedis, International LTD, ASK Ginza Bldg, 10-6, 7-Chome Ginza, Chuo-ku, Tokyo 104-0061, Japan. Telephone: (03) 3575-1611. Fax: (03) 3569-0155. Contact Kazuo Okuhara. E-mail [kazu-o@biomedis.co.jp](mailto:kazu-o@biomedis.co.jp)

**REST OF WORLD SALES:** Fran Grega, 523 Samuel Chase Way, Annapolis, MD 21401. Telephone 410-897-0297. Fax 410-897-0298. E-mail [frangrega@comcast.net](mailto:frangrega@comcast.net)

**ADVERTISING PRODUCTION:** Lippincott Williams & Wilkins, Angela Hopkins, 351 W. Camden St, Baltimore, MD 21201-2436. Telephone 410-528-4047. Fax 410-528-4452. E-mail [ahopkins@lww.com](mailto:ahopkins@lww.com). Advertising forms close 45 days before the first day of publication month.

**SPONSORED GIFT SUBSCRIPTIONS:** Contact Carol Bak, Lippincott Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201-2436. Telephone 410-528-4163. Fax 410-528-4305. E-mail [cbak@lww.com](mailto:cbak@lww.com)

**CLASSIFIED ADVERTISING:** Jennifer Williams, Lippincott Williams & Wilkins, 351 W. Camden St, Baltimore, MD 21201-2436. Telephone 1-800-528-1843. Fax 410-528-4452. E-mail [jwilliam@lww.com](mailto:jwilliam@lww.com)

Advertisements in this issue have been reviewed to comply with the principles governing advertising in American Heart Association publications. A copy of these principles is available on request. The appearance of an advertisement in an AHA publication is neither an AHA guarantee nor endorsement of the product or service or the claims for the product or service made by the advertiser.

## Secondary Services

**INDEXED OR ABSTRACTED** in Biological Abstracts, CABS, Chemical Abstracts, Current Contents, EMBASE/Excerpta Medica, and Index Medicus.

**MICROFORM EDITION** available from University Microfilms International, 300 North Zeeb Rd, Ann Arbor, MI 48106-1346. Telephone 313-761-4700. Also available from Princeton Microfilm Corporation, Alexander Rd, Box 2073, Princeton, NJ 08540. Telephone 609-452-2066.

**AUTHORIZATION TO PHOTOCOPY** items from this publication for personal and internal use, the personal or internal use of specific clients, or for educational use, is granted by the American Heart Association on the condition that the copier pay the appropriate fee to the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Dr, Danvers, MA 01923; telephone 978-750-8400; fax 978-750-4744. This consent does not extend to copying for advertising or promotional purposes, for creating new collective works, or for resale. Individuals may make single photocopies for personal, non-commercial use without obtaining permission. For all other use, permission should be sought directly from Rights & Permissions Desk, Lippincott Williams & Wilkins, 351 W. Camden St, Baltimore, MD 21201-2436; telephone 410-528-4050; fax 410-528-8550; E-mail [journalpermissions@lww.com](mailto:journalpermissions@lww.com).

Arteriosclerosis, Thrombosis, and Vascular Biology (ISSN 1079-5642) is published monthly by Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436.

GST Registration Number: 89552 4239 RT.

Printed in the USA © 2003 American Heart Association, Inc.